glp-1 liver Multiple target tissue effects of analogues on non-alcoholic fatty disease (NAFLD) and non-alcoholic steatohepatitis (NASH) Glucagon‐like peptide‐1 receptor agonists (GLP‐1

PFOS, PFOA, PFNA and PFHxS were selected as ligands, and the four targets possessing the maximum degree values in the PPI network of the intersection targets of hyperlipidemia and atherosclerosis were selected as receptors (Table S11) for molecular docking

Ltd.s once-weekly, injectable glucagon-like peptide-1 (GLP-1) agonist, XW-003 (ecnoglutide), in South Korea to treat type 2 diabetes and obesity

It most widely presents as a subungual nodule on the first toe of adolescents, elevating the nail plate and sometimes associated with onycholysis

Gonzlez-Flores D, Lpez-Pingarrn L, Castao MY, Gmez M, Rodrguez AB, Garca JJ, Garrido M

10.3390/ijms231911881 98 ZhouY.ZhouB.PacheL.ChangM.KhodabakhshiA

Originally developed to treat people with type-2 diabetes (T2DM), these drugs have proven useful for addressing a range of other conditions, from obesity to sleep apnea